BPM
CORT icon

Bowling Portfolio Management’s Corcept Therapeutics CORT Stock Holding History

Bowling Portfolio Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-36,581
Closed -$513K – 353
2018
Q3 		$513K Buy
+36,581
New +$511K 0.07% 298

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bowling Portfolio Management's CORT Position: Q4 2018 in Review

Bowling Portfolio Management sold out of Corcept Therapeutics (CORT) in Q4 2018, closing a stake of 36,581 shares — an estimated $513K sold.

Bowling Portfolio Management first reported a position in CORT in Q3 2018 and held it in 1 quarter. The position peaked at $513K in Q3 2018. 222 funds tracked by Wall St. Rank hold CORT as of Q4 2018.

  • Bowling Portfolio Management reported no remaining Corcept Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Bowling Portfolio Management sold 36,581 Corcept Therapeutics shares in Q4 2018, an estimated $513K.
  • Bowling Portfolio Management first reported a position in Corcept Therapeutics in Q3 2018 and held it in 1 quarter.
  • Bowling Portfolio Management's Corcept Therapeutics position peaked at $513K in Q3 2018.
  • 222 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2018.

Based on Bowling Portfolio Management's 13F filing for Q4 2018, filed 17 Jan 2019.